Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
12.3M
-
Shares change
-
-1.55M
-
Total reported value, excl. options
-
$16.5M
-
Value change
-
-$2.04M
-
Put/Call ratio
-
1
-
Number of buys
-
9
-
Number of sells
-
-18
-
Price
-
$1.34
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q3 2024
54 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.3M shares
of 55.7M outstanding shares and own 22.1% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (3.75M shares), VANGUARD GROUP INC (1.76M shares), ACADIAN ASSET MANAGEMENT LLC (1.07M shares), RENAISSANCE TECHNOLOGIES LLC (975K shares), Alphabet Inc. (890K shares), ADAR1 Capital Management, LLC (743K shares), BlackRock, Inc. (485K shares), GEODE CAPITAL MANAGEMENT, LLC (481K shares), Novo Holdings A/S (469K shares), and Atlas Venture Life Science Advisors, LLC (403K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.